Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Factors Affecting the Metabolic Conversion of Ciprofloxacin and Exposure to Its Main Active Metabolites in Critically Ill Patients: Population Pharmacokinetic Analysis of Desethylene Ciprofloxacin

M. Šíma, D. Bobek, P. Cihlářová, P. Ryšánek, J. Roušarová, J. Beroušek, M. Kuchař, T. Vymazal, O. Slanař

. 2022 ; 14 (8) : . [pub] 20220804

Language English Country Switzerland

Document type Journal Article

Grant support
Inter-Excellence (Action), under Grant LTAUSA-243018 Ministry of Education Youth and Sports
Cooperatio project (research area PHAR) Charles University
SVV 260523 Charles University
A1_FPBT_2022_007 Specific University Research

The objective of this prospective study was to examine the exposure to the main active metabolites of ciprofloxacin in critically ill patients and to examine the factors (demographic, laboratory and genetic) that could potentially affect the drug metabolic conversion of ciprofloxacin. The secondary aim was to develop a population pharmacokinetic model for the metabolite showing the most associations with the abovementioned factors. A total of 29 patients were treated with intravenous infusion of ciprofloxacin and enrolled on this trial. Blood samples for pharmacokinetic analysis were taken at 1, 4, and 11.5 h following the completion of the infusion. Sex, age, body weight, height, serum creatinine and bilirubin levels, and creatinine clearance (CLCR) were recorded, and polymorphisms rs2032582 and rs1045642 in the ABCB1 gene, rs4148977 in the SLCO1A2 gene and rs762551 in the CYP1A2 gene were analyzed. A three-stage parent drug-metabolite population pharmacokinetic model was developed. Median (IQR) metabolite/parent ratios of the desethylene ciprofloxacin, formyl ciprofloxacin and oxociprofloxacin were 5.86 (4.09-9.87)%, 4.08 (3.38-6.92)% and 5.91 (3.42-13.65)%, respectively. The desethylene ciprofloxacin metabolic ratio was positively associated with height (r2 = 0.2277, p = 0.0089) and CLCR (r2 = 0.2023, p = 0.0144) and negatively associated with age (r2 = 0.2227, p = 0.0112). Males had a significantly higher oxociprofloxacin metabolic ratio than females (9.14 vs 3.42%, p = 0.0043). In the desethylene ciprofloxacin population PK model, the volume of distribution decreased with age, the parent drug-metabolite transfer rate constant increased with CLCR, and the metabolite elimination rate constant decreased with age and is increased in CYP1A2 rs762551 variant allele carriers. We therefore hypothesized that the CYP1A2 inhibition by ciprofloxacin is mediated by its metabolite desethylene ciprofloxacin.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023591
003      
CZ-PrNML
005      
20221031095246.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics14081627 $2 doi
035    __
$a (PubMed)36015253
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic $1 000000026541738X
245    10
$a Factors Affecting the Metabolic Conversion of Ciprofloxacin and Exposure to Its Main Active Metabolites in Critically Ill Patients: Population Pharmacokinetic Analysis of Desethylene Ciprofloxacin / $c M. Šíma, D. Bobek, P. Cihlářová, P. Ryšánek, J. Roušarová, J. Beroušek, M. Kuchař, T. Vymazal, O. Slanař
520    9_
$a The objective of this prospective study was to examine the exposure to the main active metabolites of ciprofloxacin in critically ill patients and to examine the factors (demographic, laboratory and genetic) that could potentially affect the drug metabolic conversion of ciprofloxacin. The secondary aim was to develop a population pharmacokinetic model for the metabolite showing the most associations with the abovementioned factors. A total of 29 patients were treated with intravenous infusion of ciprofloxacin and enrolled on this trial. Blood samples for pharmacokinetic analysis were taken at 1, 4, and 11.5 h following the completion of the infusion. Sex, age, body weight, height, serum creatinine and bilirubin levels, and creatinine clearance (CLCR) were recorded, and polymorphisms rs2032582 and rs1045642 in the ABCB1 gene, rs4148977 in the SLCO1A2 gene and rs762551 in the CYP1A2 gene were analyzed. A three-stage parent drug-metabolite population pharmacokinetic model was developed. Median (IQR) metabolite/parent ratios of the desethylene ciprofloxacin, formyl ciprofloxacin and oxociprofloxacin were 5.86 (4.09-9.87)%, 4.08 (3.38-6.92)% and 5.91 (3.42-13.65)%, respectively. The desethylene ciprofloxacin metabolic ratio was positively associated with height (r2 = 0.2277, p = 0.0089) and CLCR (r2 = 0.2023, p = 0.0144) and negatively associated with age (r2 = 0.2227, p = 0.0112). Males had a significantly higher oxociprofloxacin metabolic ratio than females (9.14 vs 3.42%, p = 0.0043). In the desethylene ciprofloxacin population PK model, the volume of distribution decreased with age, the parent drug-metabolite transfer rate constant increased with CLCR, and the metabolite elimination rate constant decreased with age and is increased in CYP1A2 rs762551 variant allele carriers. We therefore hypothesized that the CYP1A2 inhibition by ciprofloxacin is mediated by its metabolite desethylene ciprofloxacin.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bobek, Daniel $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic
700    1_
$a Cihlářová, Petra $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, 166 28 Prague, Czech Republic $1 0000000165520697
700    1_
$a Ryšánek, Pavel $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic $1 0000000167271663
700    1_
$a Roušarová, Jaroslava $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic
700    1_
$a Beroušek, Jan $u Department of Anesthesiology and ICM, Second Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Prague, Czech Republic
700    1_
$a Kuchař, Martin $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, 166 28 Prague, Czech Republic $1 0000000276166352
700    1_
$a Vymazal, Tomáš $u Department of Anesthesiology and ICM, Second Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Prague, Czech Republic
700    1_
$a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic $1 0000000253577562
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 14, č. 8 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36015253 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20221031095243 $b ABA008
999    __
$a ind $b bmc $g 1853930 $s 1174879
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 8 $e 20220804 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a Inter-Excellence (Action), under Grant LTAUSA-243018 $p Ministry of Education Youth and Sports
GRA    __
$a Cooperatio project (research area PHAR) $p Charles University
GRA    __
$a SVV 260523 $p Charles University
GRA    __
$a A1_FPBT_2022_007 $p Specific University Research
LZP    __
$a Pubmed-20221010

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...